Results 41 to 50 of about 64,954 (254)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

Frontiers in Immunology, 2022
Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients.
Jennifer R. Blase, David Frame, Thomas F. Michniacki, Kelly Walkovich   +3 more
doaj   +1 more source

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

Advanced Science, EarlyView.
FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble, Wiktor Zywicki, Enrico Lucarelli, Ania Naila Guerrieri, Francesca Taraballi, Gianluca Cidonio, Claudia Di Bella, Carmine Onofrillo, Andrea J. O'Connor, Serena Duchi   +9 more
wiley   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Engraftment of sheep splenic lymphocytes into NBSGW mice and application in Brucella infection

Animal Models and Experimental Medicine, EarlyView.
A sheep splenocyte‐reconstituted mouse model (Sh‐Spl mice) was established via intravenous injection of sheep splenic lymphocytes into immunodeficient mice to evaluate Brucella infection. Abstract Background The development of immune reconstituted xenograft mouse models has addressed the limitations imposed by interspecies immunological differences in ...
Xiaowei Wang, Shicheng Wan, Yanmin Guo, Hongyu Han, Fei Luo, Dongmei Jiang, Xiaorong Yang, Quanhai Pang, Haisheng Yu, Jinlian Hua   +9 more
wiley   +1 more source

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences, 2020
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful.
Joke Verelst, Nick Geukens, Sabiha Eddarkaoui, Dorien Vliegen, Elien De Smidt, Joëlle Rosseels, Vanessa Franssens, Sofie Molenberghs, Cindy Francois, Erik Stoops, Maria Bjerke, Maria Bjerke, Sebastiaan Engelborghs, Sebastiaan Engelborghs, Mohamed Laghmouchi, Sofie Carmans, Luc Buée, Eugeen Vanmechelen, Joris Winderickx, Debby Thomas   +19 more
doaj   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis

BMC Neurology
Objective This meta-analysis synthesizes evidence from all available randomized trials and observational cohort studies evaluating the efficacy and safety of ocrelizumab compared to placebo or active comparator therapies.
Adil Nawaz, Arsalan Bakhtiyar, Muhammad Ibrahim Khan, Erum Siddiqui, Elsa Khan, Muhammad Abbas, Muhammad Saad, Muhammad Qasim, Muhammad Taha   +8 more
doaj   +1 more source

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report

Therapeutic Advances in Neurological Disorders
Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD).
Xuefen Chen, Ziyan Shi, Rui Wang, Hongyu Zhou   +3 more
doaj   +1 more source